Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX vs FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer
ChiCTR2500107832Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nanoliposomal irinotecan in colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: 18-month progression-free survival rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2500107832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107832.